Podcasts about inhibition

What does it mean to truly live well in an age of loneliness, distraction, and endless self-improvement advice? In this episode, Dru Johnson sits down with Alan Noble to discuss his new book on the seven Christian virtues and why recovering ancient wisdom may be the key to human flourishing today. Together they explore how virtues such as courage, temperance, prudence, justice, faith, hope, and love shape a life rooted in Christ rather than in modern self-help culture. The conversation examines the growing loneliness epidemic, the difference between "thin" online communities and meaningful relationships, and why many young adults struggle with agency, friendship, dating, and purpose. Noble argues that virtue is not a life hack or productivity technique but a lifelong process of spiritual formation empowered by the Holy Spirit and cultivated within Christian community. Dru and Alan also tackle the relationship between faith and works, discuss mentorship and the loss of intergenerational wisdom, and explore why courage may be one of the most important virtues for our cultural moment. From social media and smartphone habits to friendship and discipleship, this episode offers practical and theological insights for Christians seeking to live faithfully in a fragmented world. Order Alan Noble's latest book, To Live Well, here: https://www.ivpress.com/to-live-well? We are listener supported. Give to the cause here: https://hebraicthought.org/give For more articles: https://thebiblicalmind.org/ Social Links: Facebook: https://www.facebook.com/HebraicThought Instagram: https://www.instagram.com/hebraicthought Threads: https://www.threads.net/hebraicthought X: https://www.twitter.com/HebraicThought Bluesky: https://bsky.app/profile/hebraicthought.org Chapters: 00:00 Points of Resistance and Challenges in Teaching Virtues 02:40 Virtues as Pathways to Live Well in Christian Life 04:02 Grace, Works, and Righteousness in Christian Practice 05:25 Community and the Need for Thick, Committed Groups 08:33 The Problem of Thin Communities and Society's Disconnection 10:30 The Role of Wisdom and Mentorship Across Generations 13:25 The Importance of Affirmation and Love in Community 15:17 Healthy Groups and the Balance of Affirmation and Correction 16:59 Scriptural Foundations for Virtues and Character Traits 18:19 The Significance of Courage and Temperance for Young Adults 26:32 Understanding Courage in the Context of Inhibition and Risk 32:53 Practical Steps to Cultivate Virtues and Live Well 39:24 Starting the Journey Toward Virtue and Reflection 40:32 The Role of Prayer and the Holy Spirit in Virtue Formation 43:05 Closing Remarks and Final Thoughts

Harald Müller-Huesmann spricht mit Ralf-Dieter Hofheinz über GI-Highlights vom Amerikanischen Krebskongress: ctDNA-gesteuerte Adjuvanz beim Stadium-II-Kolonkarzinom, Daraxonrasib beim vorbehandelten metastasierten Pankreaskarzinom und HER2-gerichtete ADC-Daten beim fortgeschrittenen CRC im Fokus.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HRC865. CME/AAPA/IPCE credit will be available until June 3, 2027.At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HRC865. CME/AAPA/IPCE credit will be available until June 3, 2027.At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NJM865. CME/MOC/AAPA/IPCE credit will be available until May 28, 2027.ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NJM865. CME/MOC/AAPA/IPCE credit will be available until May 28, 2027.ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NJM865. CME/MOC/AAPA/IPCE credit will be available until May 28, 2027.ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NJM865. CME/MOC/AAPA/IPCE credit will be available until May 28, 2027.ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HRC865. CME/AAPA/IPCE credit will be available until June 3, 2027.At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HRC865. CME/AAPA/IPCE credit will be available until June 3, 2027.At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NJM865. CME/MOC/AAPA/IPCE credit will be available until May 28, 2027.ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HRC865. CME/AAPA/IPCE credit will be available until June 3, 2027.At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NJM865. CME/MOC/AAPA/IPCE credit will be available until May 28, 2027.ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HRC865. CME/AAPA/IPCE credit will be available until June 3, 2027.At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HRC865. CME/AAPA/IPCE credit will be available until June 3, 2027.At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HRC865. CME/AAPA/IPCE credit will be available until June 3, 2027.At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Most men completely misunderstand why their girlfriend or wife pulls back or hides her true desires in the bedroom. In this episode, guest Morgan May joins the show to tear down the psychological walls that keep women from fully letting go.We break down the real impact of cultural conditioning, the silent damage of putting a woman on a pedestal, and the exact mistakes men make that send women right back behind defensive barriers. Stop guessing what she wants and learn how to create a grounded environment where she feels safe enough to drop the act entirely.➡️ Find Morgan May at: https://www.themorganmay.comVIDEOS TO WATCH NEXT:Watch this playlist to figure out how to fix your failing marriage: https://www.youtube.com/playlist?list=PLEXcvFDdRqPuu_G8-sTLS7eXT7myvidMFWatch this playlist to help you get over your ex for good: https://www.youtube.com/playlist?list=PLEXcvFDdRqPsZ9JCTSAIkin-oMnavqNJZWatch this playlist to develop an unshakable frame and take control of your life: https://youtube.com/playlist?list=PLEXcvFDdRqPvgN8idHfGfOp3gA8Y0tMxT&si=NccZ6koKYz3hSuUz--------------------------------------------FREE EBOOKS➡️ She's Made You Weak: https://ebook.fixdeadbedrooms.com➡️ Fine... Here's How You Get Her Back: https://ebook.getoveryourex.us--------------------------------------------BOOKS AND WORKBOOKS➡️ Find all of my books here: https://mybook.to/comeonmanpod➡️ Find all of my workbooks here: https://mybook.to/RPWorkbooks--------------------------------------------FOLLOW MEFollow on TikTok - https://www.tiktok.com/@comeonmanpodFollow on Instagram - https://www.instagram.com/comeonmanpodcast/Follow on Facebook - https://www.facebook.com/comeonmanpodcastFollow on X - https://x.com/bestmenspodFollow on Gettr - https://gettr.com/user/comeonmanpodFollow on Truth - https://truthsocial.com/@comeonmanpodFollow on Substack - https://comeonmanpod.substack.com/--------------------------------------------COMMUNITIES➡️ Join The W.O.L.F. Pack: https://wolf.comeonmanpod.com/➡️ Become a Spotify Channel Subscriber: https://podcasters.spotify.com/pod/show/comeonman/subscribe--------------------------------------------

LBCT: Interleukin-6 Inhibition in Acute Myocardial Infarction at Risk of Cardiogenic Shock: A Randomized Controlled Trial

This activity was supported by an educational grant from the Bristol Myers Squibb and Johnson & Johnson Alliance. Please go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Link⁠⁠⁠⁠ and complete the evaluation to receive your CE/CME Credit. Credit is available through May 6, 2027.

In our latest episode, we discuss the use of inhibitors of IL-6 in the treatment of retinal disease with Dr. Steven M. Yeh, Stanley M. Truhlsen, Jr. , Chair of Ophthalmology a the University of Nebraska.

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Discover how dual sodium-glucose cotransporter 1/2 (SGLT1/2) inhibition can improve outcomes for your patients across the heart failure (HF) spectrum. Credit available for this activity expires: 05/15/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/beyond-sglt2-emerging-role-dual-sglt1-2-inhibition-heart-2026a1000es7?ecd=bdc_podcast_libsyn_mscpedu

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Diagnosis, workup, and the four-step treatment protocol for thyroid storm. Hosts: Annaliese Elam, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Thyroid_Storm.mp3 Download Leave a Comment Tags: Critica Care, Endocrine, Thyroid Storm Show Notes I. Pathophysiology & Diagnosis Definition: Life-threatening hypermetabolic state resulting from decompensated thyrotoxicosis. Hormonal Profile: Absolute levels of total T₄/T₃ often mirror uncomplicated thyrotoxicosis; storm is driven by rapid rate of rise, increased catecholamine sensitivity, or increased free T₄/T₃ concentrations. Clinical Presentation: Hyperpyrexia (e.g., 104.2°F) Tachycardia/Arrhythmias (e.g., 155 bpm) Altered Mentation: Agitation, delirium, or psychosis; often the primary differentiator between “storm” and “compensated” hyperthyroidism Warm, moist skin Precipitating Events: Infection, trauma, or surgery Parturition Abrupt cessation of antithyroid medications Burch-Wartofsky Point Scale (BWPS): ≥ 45: Highly suggestive of Thyroid Storm 25–44: Suggestive of impending storm < 25: Storm unlikely Note: High sensitivity but low specificity; can be skewed by unrelated febrile illness. II. Laboratory & Ancillary Findings Thyroid Panel: Characteristically low TSH with elevated free T₄ and T₃. Metabolic Abnormalities: Mild hyperglycemia (catecholamine-induced insulin inhibition) Mild hypercalcemia Elevated LFTs and leukocytosis Cardiovascular: EKG may show sinus tachycardia or atrial fibrillation with rapid ventricular response. III. Management: The Four-Step Blocking Strategy Step 1: Sympathetic Blockade (Beta Blockers) Agent of Choice: Propranolol Mechanism: Non-selective blockade; in high doses, inhibits peripheral conversion of T₄ to T₃. Dosing: PO: 60–80 mg every 4–6 hours IV: 0.5–1 mg over 10 minutes Critical Pitfall: Avoid in patients with acute decompensated heart failure with systolic dysfunction; risk of cardiovascular collapse. Step 2: Inhibition of Hormone Synthesis (Thionamides) Agent of Choice: Propylthiouracil (PTU) preferred over Methimazole in life-threatening storm. Mechanism: Blocks synthesis of new hormone and inhibits peripheral T₄-to-T₃ conversion (decreases T₃ by ~45% in 24 hours). Dosing: 200–250 mg PO every 4 hours Step 3: Inhibition of Hormone Release (Iodine) Agents: Potassium iodide (SSKI) or Lugol’s solution Critical Timing: Must wait at least 60 minutes AFTER thionamide administration. Rationale: Immediate iodine administration provides substrate for new hormone synthesis (Wolff-Chaikoff effect bypass), potentially worsening thyrotoxicosis. Step 4: Inhibition of Peripheral Conversion & Adrenal Support Agent: Glucocorticoids (Hydrocortisone) Mechanism: Inhibits peripheral T₄ to T₃ conversion and treats potential relative adrenal insufficiency. Dosing: 300 mg IV loading dose, followed by 100 mg IV every 8 hours IV. Supportive Care & Avoidance Measures Hyperpyrexia Management: Acetaminophen is the standard of care Avoid Aspirin: Salicylates displace thyroid hormone from thyroid-binding globulin (TBG), increasing free T₄/T₃ levels Volume Resuscitation: Aggressive IV fluids; patients are often profoundly dehydrated May require 3–5 liters of isotonic crystalloid per 24 hours Take Home Points I. Diagnostic Essentials Clinical Diagnosis: Based on hyperpyrexia, cardiovascular dysfunction, and altered mentation. Key Differentiator: Altered mentation (agitation, delirium, psychosis) is often the sole finding distinguishing “storm” from “compensated” thyrotoxicosis. Burch-Wartofsky Point Scale (BWPS): ≥ 45: Highly suggestive of storm. 25–44: Suggests impending storm. < 25: Storm unlikely. Note: High sensitivity, low specificity (e.g., hyperthyroid + flu can score > 45). Triggers: Infection, trauma, parturition, or abrupt cessation of antithyroid drugs. II. The Four-Step Blocking Strategy Beta Blockade (Propranolol): Dose: 60–80 mg PO q4–6h or 0.5–1 mg IV over 10 min. Action: Blocks symptoms and inhibits peripheral T4 to T3 conversion. Caution: Avoid in acute decompensated heart failure with systolic dysfunction. Thionamides (PTU): Dose: 200 to 250 mg every four hours. (note: some resources suggest a loading dose beforehand) Action: Preferred over methimazole; blocks new hormone synthesis and peripheral T4 to T3 conversion. Iodine (SSKI/Lugol’s): Timing: Must wait ≥ 60 minutes AFTER thionamide dose. Action: Blocks hormone release. Pitfall: Early iodine provides substrate for new hormone synthesis, worsening the condition. Glucocorticoids (Hydrocortisone): Dose: 300 mg IV load, then 100 mg IV q8h. Action: Blocks conversion and provides adrenal support. III. Critical Supportive Care Hyperpyrexia: Use Acetaminophen. NEVER Use Aspirin: Displaces thyroid hormone from binding proteins, acutely increasing free T4/T3 levels. Volume: Aggressive fluid resuscitation; patients may require 3–5 L/day due to profound dehydration. Read More

Former Army Ranger, buck sergeant, infantry company commander, and top law enforcement trainer, Lt. Col. Dave Grossman, joins Trending with Timmerie. Episode Guide Brain scan data & sleep deprivation. Science of video games – why/why not? (1:35) Inhibition to kill during WWII – desensitized and undeveloped empathy (15:16) Who isn’t committing violent acts (28:36) Virtual reality (35:45) What’s the idea of child free life & motherhood (45:11) Resources mentioned: Lt. Col. Grossman https://grossmanontruth.com/ Assassination Generation: Video Games, Aggression, and the Psychology of Killing https://a.co/d/0htCyrs5

Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer ahead of the ASCO 2026 plenary phase 3 data. We discuss the RAS pathway, prior unsuccessful targeting efforts and nuances on response and resistance.

If you enjoy this episode, we're sure you will enjoy more content like this on The Occult Rejects.  In fact, we have curated playlists on occult topics like grimoires, esoteric concepts and phenomena, occult history, analyzing true crime and cults with an occult lens, Para politics, and occultism in music. Whether you enjoy consuming your content visually or via audio, we've got you covered - and it will always be provided free of charge.  So, if you enjoy what we do and want to support our work of providing accessible, free content on various platforms, please consider making a donation to the links provided below.  Thank you and enjoy the episode!Links For The Occult Rejectshttps://linktr.ee/theoccultrejectsOccult Research Institutehttps://www.occultresearchinstitute.org/Cash Apphttps://cash.app/$theoccultrejectsVenmo@TheOccultRejectsBuy Me A Coffeebuymeacoffee.com/TheOccultRejectsPatreonhttps://www.patreon.com/TheOccultRejects1. Patel, A. K., et al. *Physiology, Sleep Stages*. StatPearls / NCBI Bookshelf, 2024.2. Jensen, O., & Mazaheri, A. “Shaping Functional Architecture by Oscillatory Alpha Activity: Gating by Inhibition.” *Frontiers in Human Neuroscience*, 2010.3. Cavanagh, J. F., & Shackman, A. J. “Frontal Midline Theta Reflects Anxiety and Cognitive Control: Meta-Analytic Evidence.” *Journal of Physiology-Paris*, 2015.4. Axmacher, N., et al. “Cross-Frequency Coupling Supports Multi-Item Working Memory in the Human Hippocampus.” *PNAS*, 2010.5. Lacaux, C., et al. “Sleep Onset Is a Creative Sweet Spot.” *Science Advances*, 2021.6. Horowitz, A. H., et al. “Targeted Dream Incubation at Sleep Onset Increases Post-Sleep Creative Performance.” *Scientific Reports*, 2023.7. Caporro, M., et al. “Functional MRI of Sleep Spindles and K-Complexes.” *Clinical Neurophysiology*, 2012.8. Ng, T., et al. “Bayesian Meta-Analysis Reveals the Mechanistic Role of Slow Oscillation-Spindle Coupling in Sleep-Dependent Memory Consolidation.” *eLife*, 2025.9. Datta, K., et al. “Electrophysiological Evidence of Local Sleep During Yoga Nidra Practice in Young Male Volunteers.” *Frontiers in Neurology*, 2022.10. Jensen, M. P., et al. “Brain Oscillations, Hypnosis, and Hypnotizability.” *American Journal of Clinical Hypnosis*, 2015.11. Huels, E. R., et al. “Neural Correlates of the Shamanic State of Consciousness.” *Frontiers in Human Neuroscience*, 2021.12. Ingendoh, R. M., et al. “Binaural Beats to Entrain the Brain? A Systematic Review...” *PLOS ONE*, 2023.13. Páez, A., et al. “Sleep Spindles and Slow Oscillations Predict Cognition and Biomarkers of Neurodegeneration in Mild to Moderate Alzheimer's Disease.” *Alzheimer's & Dementia*, 2025.14. Askitopoulou, H. “Sleep and Dreams: From Myth to Medicine in Ancient Greece.” *Journal of Anesthesia History*, 2015.15. Pavli, A. “Asclepieia in Ancient Greece: Pilgrimage and Healing.” *Journal of Integrative Medicine and Research*, 2024.Also want to remind people about the website, if you're into reading we have tons of information by multiple contributors, and we got t-shirts up on the site if you're interested. Fun fact, the art is all based on the eyeball. Now let me introduce the rest of the panel and guests.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WEW865. CME/AAPA/IPCE credit will be available until May 19, 2027.Leveraging Recent Evidence on PCSK9 Inhibition: Strategies to Address Clinical Challenges for Meeting LDL-C Targets In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WEW865. CME/AAPA/IPCE credit will be available until May 19, 2027.Leveraging Recent Evidence on PCSK9 Inhibition: Strategies to Address Clinical Challenges for Meeting LDL-C Targets In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WEW865. CME/AAPA/IPCE credit will be available until May 19, 2027.Leveraging Recent Evidence on PCSK9 Inhibition: Strategies to Address Clinical Challenges for Meeting LDL-C Targets In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WEW865. CME/AAPA/IPCE credit will be available until May 19, 2027.Leveraging Recent Evidence on PCSK9 Inhibition: Strategies to Address Clinical Challenges for Meeting LDL-C Targets In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WEW865. CME/AAPA/IPCE credit will be available until May 19, 2027.Leveraging Recent Evidence on PCSK9 Inhibition: Strategies to Address Clinical Challenges for Meeting LDL-C Targets In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WEW865. CME/AAPA/IPCE credit will be available until May 19, 2027.Leveraging Recent Evidence on PCSK9 Inhibition: Strategies to Address Clinical Challenges for Meeting LDL-C Targets In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Amanda Muir from the Department of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, and University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA, on the paper "FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis" published in paper copy in Gut in May 2026. Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://bit.ly/4rRJeUI).  

Mike Sharma, MD, MSc, FRCPC - Deepening the Dialogue on the Latest Data for Factor XIa Inhibition: Is It Time to Shift the Paradigm in Secondary Stroke Prevention?

Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition

Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition

Jonathan Barratt, PhD, FRCP - From Mechanisms to Action: Exploring the Therapeutic Potential of Complement Inhibition in IgA Nephropathy

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

We've all seen it: the acute ACL patient who drags their leg into the clinic, unable to squeeze their quad to save their life. We call it Arthrogenic Muscle Inhibition (AMI), and for years, we've treated it as a stubborn, long-term enemy. But a fascinating new study from the American Journal of Sports Medicine suggests we might be overcomplicating it.Researchers analyzed 300 acute ACL patients and found that while AMI is incredibly common (affecting over half of patients), it's also surprisingly fragile. In fact, they found that nearly 80% of cases could be fully reversed in a single session with simple exercises. In this episode, we dive into the 'Red Flags' that predict quad shutdown—including one common sleeping habit you need to ban immediately—and how to flip the switch back on for your patients.To see full show notes and more, head to: https://mikereinold.com/risk-factors-of-arthrogenic-muscle-inhibition----------ACL Rehab MasterclassMy new course on the complete guide to criteria-based ACL rehab testing in return to sport is almost here.  Sign up for the presale list for a huge VIP discount and to be notified first:https://mikereinold.com/acl Click Here to View My Online CoursesWant to learn more from me? I have a variety of online courses on my website!Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the show_____Want to learn more?  Check out my blog, podcasts, and online coursesFollow me:  Instagram  |  Twitter  |  Facebook  |  Youtube

We love to hear from our listeners. Send us a message.On Episode 127 of Cell & Gene: The Podcast, Carlos Buesa, Ph.D., Founder and Chairman of the Board at Oryzon talks to Host Erin Harris about how targeting LSD1 is unlocking new treatment approaches across oncology, CNS disorders, and sickle cell disease, with promising early clinical data and a strategy grounded in precision epigenetics.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Cancer has long been understood through a variety of biological frameworks, including genetic mutations, dysregulated signaling pathways, and uncontrolled cell proliferation. Yet, these models often capture the visible consequences of disease rather than the deeper metabolic dependencies that sustain tumor survival. Despite major advances in targeted therapies, a central challenge remains: what underlying mechanisms make cancer cells vulnerable to treatment, and how can these vulnerabilities be exploited more effectively? Increasing attention has shifted toward cellular metabolism—particularly lipid regulation and energy-sensing pathways such as AMPK—as critical determinants of tumor behavior. Scientists are now taking a closer look at how metabolism works together with stress responses like autophagy—and how this connection could be used to develop better cancer treatments. A new research paper was published in Volume 17 of Oncotarget, titled “The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.” The study was led by first author Michael R. Booth and corresponding author Paul Dent from Virginia Commonwealth University, in collaboration with Laurence Booth and Jane L. Roberts from Virginia Commonwealth University and John M. Kirkwood from the University of Pittsburgh Cancer Institute. Full blog - https://www.oncotarget.org/2026/04/21/scd1-inhibition-strategy-shows-potent-synergy-with-regorafenib-and-metformin-in-tumor-cell-killing/ Paper DOI - https://doi.org/10.18632/oncotarget.28861 Correspondence to - Paul Dent - paul.dent@vcuhealth.org Abstract video - https://www.youtube.com/watch?v=lmX_c2e_-HY Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28861 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, macroautophagy, ER stress, aramchol, regorafenib, BID To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this podcast, experts April K.S. Salama, MD; Omid Hamid, MD; James M.G. Larkin, MD, PhD; and Sapna Patel, MD; discuss the data for immune checkpoint inhibitors used to treat advanced cutaneous squamous cell carcinoma, including a review of PD-1 versus PD-L1 inhibition.

Featuring perspectives from Prof Karim Fizazi and Dr Daniel George, moderated by Dr Elisabeth I Heath, including the following topics: Introduction (0:00) Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr George (3:25) Targeting AKT in Metastatic Prostate Cancer — Prof Fizazi (32:54) Tolerability and Other Practical Considerations with Capivasertib — Dr Heath (1:03:15) CME information and select publications